DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Tesis doctoral (DoctoralThesis)
Molecular mechanisms and therapeutic applications of interleukin-13 receptor α2 and cadherin-6 in cancer progression, Mecanismos moleculares y aplicaciones terapéuticas del receptor a2 de la interleukina 13 y cadherina 6 en progresión tumoral
Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología. Fecha de Lectura: 18-06-2024. Programa de Doctorado en Biología, [EN] According to the World Health Organization, cancer is the second cause of death worldwide before the age of 70, only surpassed by cardiovascular disease. In 2020, 19.3 million new cancer cases and almost 10 million cancer-related deaths were reported globally. On one hand, glioblastoma (GBM) is the most common malignant primary brain tumor in adults, with an incident of 3 to 4 cases out of 100,000 people. The median overall survival for patients is between 15 and 16 months, and the 5-year survival falls around 7.2%. On the other hand, metastasis, defined as the growth of cancer cells in different organs from the one where the cancer originated, is the final step of cancer. It is estimated that around 90% of cancer-related deaths are directly related to metastatic disease. The huge heterogeneity of cancer, together with the dismal prognosis of GBM and metastatic tumors, raises the necessity of novel therapeutic options that lead to an increase in the survival of cancer patients. Previous results reported by our group highlighted the importance of interleukin-13 (IL-13) signaling through IL-13 receptor α2 (IL13Rα2) to promote colorectal cancer (CRC) metastasis. Likewise, we demonstrated the ability of therapeutic peptides (D1 peptide) and monoclonal antibodies (mAbs) (5.5.4 and 4.4.2) to specifically target IL-13/IL13Rα2 pathway and prevent metastasis. On the other hand, our group described the role of cadherin-17 (CDH17) and cadherin-5 (CDH5), that contain an RGD motif, in breast cancer and melanoma metastasis, and the ability of the anti-RGD 6.6.1 mAb to prevent metastasis. We also described the role of cadherin-6 (CDH6) to regulate α2β1 integrin-mediated adhesion and invasion in ovarian and renal cancer. Therefore, the main objective of this Doctoral Thesis was to investigate the role of IL13Rα2, CDH6 and their related proteins in GBM and metastatic tumors to decipher their molecular mechanisms and find novel molecular targets with therapeutic potential. First, we demonstrated the value of inhibiting IL-13/IL13Rα2 signaling using D1 peptide and 5.5.4 mAb. The use of these therapeutic molecules inhibited IL-13/IL13Rα2-mediated metastatic capacities and activation of downstream mediators in cancer cells. In addition, 5.5.4 mAb increased the survival of mice with lung cancer. In collaboration with Protein Alternatives SL, we generated the recombinant versions of 5.5.4 and 4.4.2 mAbs (traditionally generated by hybridoma production) and tested their efficacy in vitro and in vivo. To delve deeper into the IL-13/IL13Rα2 pathway, we investigated the interaction network of IL13Rα2 using two different approaches: immunoprecipitation (IP) and proximity-dependent biotin identification (BioID). Using these techniques, we found PTP1B as a relevant IL13Rα2 interactor and deciphered the specific site by which IL13Rα2 binds to PTP1B. We demonstrated the role of PTP1B within the IL-13/IL13Rα2 signaling pathway, as PTP1B inhibition reduced IL-13/IL13Rα2-mediated metastatic capacities and activation of downstream mediators (FAK, Src, AKT and ERK1/2). Using claramine, a well-done PTP1B specific inhibitor, we mimicked the effects of PTP1B silencing over IL-13/IL13Rα2-induced metastatic capacities. In vivo, claramine completely protected mice from CRC liver metastasis and significantly extended lifespan of GBM-bearing mice. Given the importance of PTP1B as IL13Rα2 interactor and therapeutic target, we followed the same strategy and studied the PTP1B protein interaction network using IP and BioID and found a relevant involvement of PTP1B interactors in the NF-κB pathway., [EN] Then, we investigated the phosphorylation changes caused by IL-13 treatment through PTP1B signaling. We demonstrated that phosphorylation changes in SHN3, a transcription factor that can bind to κB motifs in the DNA, are executed by the action of a specific kinase, CSKN2, in response to IL-13 signaling through PTP1B. We identified SHN3 as a downstream mediator of IL-13/IL13Rα2/PTP1B pathway that plays a crucial role in the interplay between Wnt and NF-κB signaling pathways in cancer cells that express IL13Rα2. SHN3 regulates tumor growth in IL13Rα2-positive cancer cells and correlates with lower prognosis in different types of human cancers. Our data have uncovered a great part of the IL-13/IL13Rα2/PTP1B signaling pathway and provided a link between the IL-13/PTP1B/Src pathway and the already described IL-13/AP-1 pathway. Then, in collaboration with the research group of Irina V Balyasnikova (Northwestern University), we aimed to modulate the surface expression of IL13Rα2 to enhance the efficacy of bi-specific T cell engagers (BiTEs) highly specific to IL13Rα2. We demonstrated the ability of histone deacetylase inhibitors (HDACi) to modulate the expression of IL13Rα2 in the surface of glioma cells. Treatment of glioma cells with panobinostat and romidepsin, the most efficient compounds tested, increased the efficiency of T cells to kill glioma cells in the presence of BiTE, as well as T cell activation. On the other hand, we studied the role of CDH6 in omental and bone metastasis, as CDH6 is highly expressed in ovarian and renal cancers and is involved in bone metastasis development. We generated CDH6-stably silenced ovarian carcinoma cells and observed a decrease in the metastatic capacities in vitro and a reduced homing capacity to mouse liver and lungs, as well as in the activation of Wnt pathway. However, we observed an increased capacity of CDH6-silenced cells to perform omental metastasis. Using 6.6.1 mAb in two different bone metastasis mouse models, we demonstrated its capacity to decrease the development of bone metastasis and increase mice survival. Finally, we investigated the transcriptional changes caused by CDH6 silencing in ovarian cancer cells and found the involvement of the dysregulated genes in the epithelial to mesenchymal transition (EMT), KRAS signaling, hypoxia and apoptosis, among other functions. We investigated the SPANX family of genes, that was found to be very downregulated in the CDH6-silenced cells. Silencing of SPANXB1, the most downregulated gene among the SPANX family, hindered the metastatic capacities of ovarian carcinoma cells both in vitro and in vivo. We observed that SPANXB1 behavior was like others stem cell markers, suggesting a regulatory loop between cadherins and stemness factors. In conclusion, this Doctoral Thesis describes novel molecular mechanisms and therapeutic applications to target GBM and metastatic cancers. We have uncovered a great part of IL 13/IL13Rα2 signaling pathway and demonstrated the therapeutic value of IL13Rα2, PTP1B and SHN3. We have provided a very relevant link between IL13Rα2 and important oncogenic pathways, such as Wnt/β-catenin, NF-κB and MMP9. We have contributed to describe the role of CDH6 in omental and bone metastasis and proposed SPANX protein family as a novel therapeutic target., Ángela Martín-Regalado recibió el apoyo de una beca FPU (FPU 18/05766-MEFP). Esta Tesis Doctoral fue financiada por el proyecto RTI2018-095055-B-100 del MICYT y los proyectos PID2021-122227OB-I00 y CPP2021-008337 del MCIN/AEI/10.13039/501100011033 utilizando fondos de Next Generation EU/PRTR., Peer reviewed, Modelo experimental animal, Modelo experimental alternativo-NAM, Mamíferos - Roedores, in silico, in vitro - Tipos celulares - líneas inmortalizadas humanas, in vitro - Tipos celulares - líneas celulares primarias